Hinge binder modification into imidazopyridine for targeting actionable mutations of RET kinase
Arunkranthi Maturi1, Vinay Pogaku1, Surendra Kumar1
1Gachon Institute of Pharmaceutical Science and Department of Pharmacy, College of Pharmacy, Gachon University Yeonsu-gu Incheon Republic of Korea kmh0515@gachon.ac.kr.
None:
The RET proto-oncogene is a critical oncogenic driver in the development of several types of cancer. Despite the existence of clinically approved RET inhibitors, their limited response rates and emergence of resistance due to diverse actionable mutations underscore the need for novel therapeutics. Herein, we report substituted imidazo[1,2-a]pyridine derivatives as new RET inhibitors exhibiting IC50 values as low as 11 nM against three distinct point mutations and three important RET fusions. The binding mode and measured potency were elucidated by induced-fit docking simulations and cardiotoxicity was evaluated.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...


